AngioDynamics, Inc.
NASDAQ•ANGO
CEO: Mr. James C. Clemmer
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2004-06-01
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
連絡先情報
時価総額
$441.44M
PER (TTM)
-16.0
56.8
配当利回り
--
52週高値
$13.99
52週安値
$8.36
52週レンジ
順位47Top 61.9%
3.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q2 2026 データ
売上高
$79.43M+9.04%
直近4四半期の推移
EPS
-$0.15-42.31%
直近4四半期の推移
フリーCF
$4.24M+152.92%
直近4四半期の推移
2026 Q2 決算ハイライト
主なハイライト
Net Sales Growth Strong Six months net sales grew 10.6% to $155.1 M; Med Tech sales increased 19.1% over prior period.
Gross Margin Expansion Noted Total gross margin percentage improved 120 basis points to 55.8% for the six months ended November 30, 2025.
Net Loss Significantly Reduced Six months net loss decreased $6.3 M to $17.3 M, resulting in diluted loss per share of $0.42.
Operating Cash Flow Improved Cash used in operating activities improved $4.5 M to $(11.3) M for six months, reflecting better working capital.
リスク要因
Port Product Liability Claims Defending approximately 268 Port Product Liability Claims; future litigation outcomes could materially impact financial estimates.
Sustained Profitability Lacking Full valuation allowance maintained on deferred tax assets; sustained profitability needed to potentially release allowance.
R&D Spending Increased R&D expense increased $1.5 M for six months to $14.2 M due to timing of clinical trial spending and projects.
Restructuring Charges Recorded Total restructuring charges reached $28.0 M related to manufacturing footprint optimization announced on January 5, 2024.
見通し
Debt Position Remains Strong Zero outstanding debt as of November 30, 2025; $25.0 M secured revolving credit facility remains fully available.
CEO Transition Underway CEO transition underway; search committee established for successor, currently contemplated retirement date is November 30, 2026.
Liquidity Sufficient Short Term Current liquidity sufficient for next 12 months; external financing may be required for future acquisitions of businesses.
Restructuring Completion Expected Manufacturing footprint restructuring plan modification expected completion by end of fiscal year 2026, maintaining NY presence.
同業比較
売上高 (TTM)
$854.40M
$381.14M
$307.31M
粗利益率 (最新四半期)
100.0%
83.5%
73.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| RAPT | $959.26M | -14.8 | -61.8% | 1.6% |
| OCGN | $803.35M | -11.3 | -2626.4% | 74.8% |
| OMER | $799.05M | -6.2 | 57.3% | 103.2% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.3%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年3月31日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし